SkinBioTherapeutics PLC Total Assets
SkinBioTherapeutics PLC total assets. Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) holds total assets worth GBX12.13 Million GBX (≈ $1.48K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SkinBioTherapeutics PLC stock valuation for the company's overall valuation and market capitalisation.
Total Assets of SkinBioTherapeutics PLC (2016–2025)
Total assets of SkinBioTherapeutics PLC from 2016 to 2025. This chart illustrates how SkinBioTherapeutics PLC's total assets have evolved over time, based on quarterly financial data. See today's stock price for SkinBioTherapeutics PLC for real-time trading data and today's change.
SkinBioTherapeutics PLC - Asset Composition Analysis
SkinBioTherapeutics PLC Total Assets Breakdown (June 2025)
SkinBioTherapeutics PLC total assets breakdown as of June 2025. SkinBioTherapeutics PLC's total assets of GBX12.13 Million consist of 58.6% current assets and 41.4% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 39.4% |
| Accounts Receivable | GBX1.41 Million | 11.6% |
| Inventory | GBX800.15K | 6.6% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX1.87 Million | 15.4% |
| Goodwill | GBX2.42 Million | 20.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how SkinBioTherapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of SkinBioTherapeutics PLC to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SkinBioTherapeutics PLC's current assets represent 58.6% of total assets in 2025, a decrease from 67.8% in 2016.
- Cash Position: Cash and equivalents constituted 39.4% of total assets in 2025, down from 60.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 32.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 20.0% of total assets.
SkinBioTherapeutics PLC Competitors by Total Assets
Key competitors of SkinBioTherapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
SkinBioTherapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.84 | 0.93 | 7.70 |
| Quick Ratio | 4.29 | 0.66 | 7.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX5.64 Million | GBX-133.29K | GBX2.04 Million |
SkinBioTherapeutics PLC - Advanced Valuation Insights
This section examines the relationship between SkinBioTherapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 132.5% |
| Total Assets | GBX12.13 Million |
| Market Capitalization | $307.45K USD |
Valuation Analysis
Below Book Valuation: The market values SkinBioTherapeutics PLC's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SkinBioTherapeutics PLC's assets grew by 132.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual total assets of SkinBioTherapeutics PLC from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | GBX12.13 Million ≈ $1.48K |
+132.51% |
| 2024-06-30 | GBX5.22 Million ≈ $634.52 |
+101.02% |
| 2023-06-30 | GBX2.59 Million ≈ $315.65 |
-15.91% |
| 2022-06-30 | GBX3.08 Million ≈ $375.35 |
-46.21% |
| 2021-06-30 | GBX5.73 Million ≈ $697.78 |
+106.99% |
| 2020-06-30 | GBX2.77 Million ≈ $337.11 |
-29.53% |
| 2019-06-30 | GBX3.93 Million ≈ $478.35 |
+7.70% |
| 2018-06-30 | GBX3.65 Million ≈ $444.13 |
-15.74% |
| 2017-06-30 | GBX4.33 Million ≈ $527.10 |
+922.98% |
| 2016-06-30 | GBX423.49K ≈ $51.53 |
-- |
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more